Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2022

View Archived Issues

Shujing Biopharma, Jiangsu Nhwa Pharmaceutical patent 5-HT2A/DRD2 antagonists

Vertex Pharmaceuticals describes new CFTR modulators

New K(Ca) 1.1 channel activators identified at Gwangju Institute of Science and Technology

Dana-Farber Cancer Institute synthesizes SRPK1/SRPK2 inhibitors

Merck & Co. discovers diacylglycerol acyltransferase type 2 inhibitors

M1 mAChR antagonism attenuates opioid drug seeking behaviors in rat

TRAIL protein levels may predict response to acamprosate in alcohol use disorder

CDK7 inhibitor GTAEXS-617 shows potent antitumor activity in vivo

FDA awards orphan drug designation to AB-001 for pancreatic cancer and AML

ALTA-2530 shows preclinical efficacy as potential treatment of bronchiolitis obliterans syndrome

DGKk gene therapy rescues brain lipid profiles and long-term behavior in fragile X syndrome mice

Researchers discover HDAC1 as the cause of immune abnormalities in autistic mouse models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...